Paul Peter Tak, M.D., Ph.D., FMedSci
2023
In 2023, Paul Peter Tak, M.D., Ph.D., FMedSci earned a total compensation of $1.5M as Chief Executive Officer at Candel Therapeutics, a 20% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $134,000 |
|---|---|
| Option Awards | $189,558 |
| Salary | $670,000 |
| Stock Awards | $176,506 |
| Other | $314,695 |
| Total | $1,484,759 |
FMedSci received $670K in salary, accounting for 45% of the total pay in 2023.
FMedSci also received $134K in non-equity incentive plan, $189.6K in option awards, $176.5K in stock awards and $314.7K in other compensation.
Rankings
In 2023, Paul Peter Tak, M.D., Ph.D., FMedSci's compensation ranked 803rd out of 3,006 executives tracked by ExecPay. In other words, FMedSci earned more than 73.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 803 out of 3,006 | 73rd |
Division Manufacturing | 472 out of 1,650 | 71st |
Major group Chemicals And Allied Products | 322 out of 918 | 65th |
Industry group Drugs | 314 out of 881 | 64th |
Industry Biological Products, Except Diagnostic Substances | 100 out of 213 | 53rd |
Source: SEC filing on May 30, 2024.
FMedSci's colleagues
We found two more compensation records of executives who worked with Paul Peter Tak, M.D., Ph.D., FMedSci at Candel Therapeutics in 2023.